Urologische Tumoren

Univ-Prof. Dr. med. Peter Albers

Prof. Dr. med. dr. h.c. Axel Heidenreich

Black PC et al. Phase II trial of atezolizumab in BCG- unresponsive non- muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).
Balar AV et al. Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette- Guérin (BCG) unresponsive, high-risk (HR) non- muscle- invasive bladder cancer (NMIBC): Over two years follow- up of KEYNOTE- 057 .
Hussain MHA et al. Imvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
Kaimakliotis HZ et al. Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (IaUC): Interim results from the cisplatin (C)- ineligible cohort of GU14- 188.
Powles T et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
Rosenberg JE et al. Study EV- 103: Durability results of enfortumabvedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Pal SK et al. Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum- containing chemotherapy: Results from cohort 2 of the COSMIC- 021 study.
Siefker-Radtke AO et al. ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.
Galsky MD et al. Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130.
Lerner SP et al. Association of molecular subtypes with pathologic response in a phase II study of co- expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle- invasive bladder cancer (SWOG S1314; NCT02177695).

Urologische Tumoren Highlight

404 Not Found

Die Seite wurde leider nicht gefunden

Gründe dafür könnten sein, dass Sie eine falsche oder veraltete URL aufgerufen haben. Oder aber die Seite wurde von uns umbenannt, verschoben und archiviert. Versuchen Sie es noch einmal und aktualisieren Sie die Seite.

Andernfalls verwenden Sie bitte den folgenden Link, um die von Ihnen gewünschten Inhalte zu finden

Zur Startseite